Article Page

Abstract

This paper describes an integrated platform for machine learning and big data analysis. The integrated platform is configured in a way that builds a large distributed data processing environment in the computing environment that makes up the NVIDIA AI platform. In addition, this paper describes the background of this idea selection and the use of the software to build the unified platform. The technical details are shown in terms of how to create the proposed platform. In the anlaysis section, the methodology is provided and also the steps are explained as to how to use this integration platform. Finally, the expected effects are elaborated in the Unified Platform for AI and Big Data semi-empirical D&C Analytics strategy as an improvement of the linear interaction energy model with electrostatic salvation for the generation TP4 (AMP) antimicrobial peptide mimetic pharmacoligand, against H.Pylori infection within accurate enthalpy values.

Keywords

semi-empirical: D&C strategy;improvement;linear interaction energy; model continuum; electrostatic salvation;in silico; antimicrobial;peptide mimetic;pharmacoligand;Helicobacter Pylori; infection; accurate enthalpy values; Unified Platform; AI; Big Data; semi-empirical; D&C Analytics; linear interaction energy; electrostatic salvation; generation TP4 (AMP); antimicrobial peptide mimetic; pharmacoligand, H.Pylori infection; accurate enthalpy values;

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) Unified Platform for AI and Big Data semi-empirical D&C Analytics strategy as an improvement of the linear interaction energy model with electrostatic salvation for the generation TP4 (AMP) antimicrobial peptide mimetic pharmacoligand, against H.Pylori infection within accurate enthalpy values.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available